Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG daily Stock Chart
CRISPR Therapeutics AG
Index- P/E86.14 EPS (ttm)0.75 Insider Own1.70% Shs Outstand60.85M Perf Week1.60%
Market Cap3.82B Forward P/E- EPS next Y-5.20 Insider Trans-14.08% Shs Float48.27M Perf Month29.90%
Income45.50M PEG- EPS next Q-0.98 Inst Own60.10% Short Float8.85% Perf Quarter21.95%
Sales289.40M P/S13.21 EPS this Y134.10% Inst Trans12.99% Short Ratio4.54 Perf Half Y-5.35%
Book/sh14.56 P/B4.46 EPS next Y-11.00% ROA5.50% Target Price73.82 Perf Year74.32%
Cash/sh15.11 P/C4.30 EPS next 5Y- ROE6.50% 52W Range32.30 - 74.00 Perf YTD6.64%
Dividend- P/FCF96.56 EPS past 5Y54.00% ROI4.90% 52W High-12.74% Beta2.30
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low99.91% ATR3.94
Employees304 Current Ratio16.90 Sales Q/Q-33.30% Oper. Margin7.40% RSI (14)58.55 Volatility5.79% 6.89%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.30% Profit Margin15.70% Rel Volume0.69 Prev Close64.95
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume941.93K Price64.57
Recom2.20 SMA203.81% SMA5021.47% SMA20023.05% Volume494,756 Change-0.59%
Mar-05-20Initiated Stifel Hold $52
Feb-03-20Downgrade Evercore ISI Outperform → In-line $85 → $52
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jun-03-20 07:54AM  
Jun-02-20 10:00AM  
Jun-01-20 11:46AM  
May-28-20 11:31AM  
May-26-20 08:30AM  
May-19-20 05:09AM  
May-18-20 06:32PM  
May-16-20 10:00AM  
May-15-20 08:30AM  
May-14-20 09:02AM  
May-12-20 03:40PM  
May-11-20 05:19PM  
May-07-20 08:00AM  
Apr-30-20 06:27AM  
Apr-28-20 07:45PM  
Apr-27-20 12:31PM  
Apr-24-20 11:41AM  
Apr-18-20 09:56AM  
Apr-03-20 06:34PM  
Mar-27-20 10:47AM  
Mar-23-20 05:50PM  
Mar-10-20 05:50PM  
Mar-02-20 01:03AM  
Feb-26-20 04:05PM  
Feb-19-20 07:59AM  
Feb-13-20 08:05AM  
Feb-12-20 06:55PM  
Feb-11-20 02:26PM  
Feb-06-20 05:45PM  
Feb-04-20 02:56PM  
Jan-31-20 05:45PM  
Jan-28-20 10:35AM  
Jan-17-20 02:09PM  
Jan-14-20 05:11PM  
Jan-10-20 09:42AM  
Jan-09-20 03:20PM  
Jan-06-20 11:00PM  
Jan-03-20 05:50PM  
Dec-30-19 04:07PM  
Dec-20-19 04:30PM  
Dec-11-19 03:41PM  
Dec-10-19 03:08PM  
Dec-04-19 05:31PM  
Dec-03-19 01:03AM  
Nov-29-19 12:15PM  
Nov-27-19 05:33PM  
Nov-26-19 07:06PM  
Nov-25-19 06:55PM  
Nov-22-19 03:12PM  
Nov-21-19 10:24AM  
Nov-20-19 09:18PM  
Nov-19-19 05:20PM  
Nov-14-19 01:27PM  
Nov-13-19 10:00AM  
Nov-08-19 02:20PM  
Nov-04-19 05:05PM  
Oct-31-19 12:33PM  
Oct-29-19 04:05PM  
Oct-28-19 02:58PM  
Oct-25-19 12:06PM  
Oct-23-19 04:24PM  
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerJun 01Option Exercise1.8117,27531,268188,801Jun 03 05:32 PM
Kulkarni SamarthChief Executive OfficerJun 01Sale64.6817,2751,117,266171,526Jun 03 05:32 PM
Ho Tony WExecutive VP, Head of R&DMay 26Sale70.146,100427,85440,905May 27 04:32 PM
Novak RodgerPresidentMay 26Sale70.2736,6162,573,006748,007May 27 04:34 PM
Novak RodgerPresidentMay 22Sale70.0113,384937,014784,623May 27 04:34 PM
Ho Tony WExecutive VP, Head of R&DMay 22Sale70.0560042,03047,005May 27 04:32 PM
Kulkarni SamarthChief Executive OfficerMay 20Option Exercise1.8110,69319,354182,219May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 20Sale65.2810,693698,039171,526May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 19Option Exercise1.814,3077,796175,833May 21 04:35 PM
Novak RodgerPresidentMay 19Sale65.0050,0003,250,000798,007May 21 04:37 PM
Kulkarni SamarthChief Executive OfficerMay 19Sale65.164,307280,644171,526May 21 04:35 PM
Klein Lawrence OttoCBO & COOMay 11Option Exercise5.8625,000146,50045,000May 13 04:38 PM
Klein Lawrence OttoCBO & COOMay 11Sale60.4025,0001,509,97120,000May 13 04:38 PM
Kulkarni SamarthChief Executive OfficerDec 16Option Exercise1.818,00014,480172,320Dec 18 04:05 PM
Novak RodgerPresidentNov 19Option Exercise14.4333,618485,10833,618Nov 21 04:09 PM
CAGNONI PABLO JDirectorNov 19Option Exercise5.597,50041,9257,500Nov 21 04:07 PM
Bolzon Bradley J PhDDirectorNov 19Sale67.4128,2551,904,783596,741Nov 21 07:53 PM
Bolzon Bradley J PhDDirectorNov 19Sale67.4113,745926,6050Nov 21 07:53 PM
Novak RodgerPresidentNov 19Sale70.0033,6182,353,2600Nov 21 04:09 PM
CAGNONI PABLO JDirectorNov 19Sale62.007,500465,0000Nov 21 04:07 PM
CAGNONI PABLO JDirectorNov 12Option Exercise5.597,50041,9257,500Nov 13 04:30 PM
CAGNONI PABLO JDirectorNov 12Sale55.007,500412,5000Nov 13 04:30 PM
CAGNONI PABLO JDirectorOct 30Option Exercise5.597,50041,9257,500Nov 01 06:35 PM
Bolzon Bradley J PhDDirectorOct 30Sale51.8921,0001,089,67513,745Nov 01 06:34 PM
CAGNONI PABLO JDirectorOct 30Sale52.007,500390,0000Nov 01 06:35 PM
Klein Lawrence OttoChief Business OfficerJul 11Option Exercise5.868,42149,34728,421Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 11Sale50.018,421421,17120,000Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 10Option Exercise5.8611,57967,85331,579Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 10Sale50.0211,579579,18220,000Jul 12 04:13 PM
Novak RodgerPresidentJul 10Sale50.0050,0002,500,065848,007Jul 12 04:10 PM
Kulkarni SamarthChief Executive OfficerJun 17Option Exercise1.8120,00036,200185,801Jun 19 04:15 PM
Kulkarni SamarthChief Executive OfficerJun 17Sale46.0020,000920,000165,801Jun 19 04:15 PM
Novak RodgerPresidentJun 10Sale45.0050,0002,250,000898,007Jun 12 04:16 PM